Dr. Sultzer is Professor in the Department of Psychiatry and Biobehavioral Sciences at the UCLA School of Medicine. He directs the UCLA Geriatric Psychiatry Fellowship Training Program and the Gero/Neuropsychiatry Division at VA Greater Los Angeles Healthcare System. He is recognized widely for his research activities to better understand the phenomenology, pathophysiology, and treatment of Alzheimer’s disease. He has received independent project research support from the NIMH and other funding sources to study psychiatric symptoms in patients with Alzheimer’s disease. His work using fluorodeoxyglucose positron emission tomography (PET) has demonstrated that specific clinical symptoms, including psychosis, are associated with regional metabolic dysfunction in patients with Alzheimer’s disease. These results indicate that psychiatric symptoms are fundamental expressions of the degenerative process. Recently, he has used PET imaging to better understand the neurobiological mechanisms involved in medication treatment response in Alzheimer’s disease. He has also completed clinical trials to compare the efficacy and adverse effects of medications for the treatment of psychosis and agitated behaviors in patients with dementia, and is one of the few researchers to have examined the differential response of specific clinical symptoms to pharmacologic interventions. Other areas of research interest include MRI imaging in Alzheimer’s disease, psychosis in older persons without cognitive disorders, and mood symptoms in patients with neuropsychiatric conditions. Dr. Sultzer received his medical degree from the University of North Carolina, and completed his residency training in psychiatry and fellowship training in neurobehavior at UCLA. He is prominently involved in graduate medical education at UCLA and the West Los Angeles VA Medical Center. He lectures widely and has published numerous articles in the medical literature. He has also received several awards for his research work, and is recognized nationally for his academic activities related to geriatric psychiatry and Alzheimer’s disease. Publications: Sultzer DL, Lavretsky H Antipsychotic medication in the elderly. : Kaplan HI, Sadock BJ (eds), Comprehensive Textbook of Psychiatry, 8th Edition 2005; . Sultzer, DL Psychosis and antipsychotic medications in Alzheimer's disease: clinical management and research perspectives.. Dementia and geriatric cognitive disorders. . 2004; 17(1-2): 78-90. Schneider, LS Ismail, MS Dagerman, K Davis, S Olin, J McManus, D Pfeiffer, E Ryan, JM Sultzer, DL Tariot, PN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.. Schizophrenia bulletin. . 2003; 29(1): 57-72. Sultzer, DL Chen, ST Brown, CV Mahler, ME Cummings, JL Hinkin, CH Mandelkern, MA Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findings.. The Journal of neuropsychiatry and clinical neurosciences. . 2002; 14(3): 262-9. Feil D, Chuang K, Sultzer DL Valproate-induced hyperammonemia as a cause of altered mental status. Am J Geriatr Psychiatry 2002; 10: 476-478. Harwood DG, Sultzer DL “Life is not worth living”: hopelessness in Alzheimer’s disease. J Geriatr Psychiatry Neurol 2002; 15: 38-43. Sultzer DL, Gray KF, Gunay I, Wheatley MV, Mahler ME Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?. J Am Geriatr Soc 2001; 49: 1294-1300. Bartzokis, G Cummings, JL Sultzer, D Henderson, VW Nuechterlein, KH Mintz, J White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study.. Archives of neurology. . 2003; 60(3): 393-8. Sultzer, DL Brown, CV Mandelkern, MA Mahler, ME Mendez, MF Chen, ST Cummings, JL Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease.. The American journal of psychiatry. . 2003; 160(2): 341-9.